drugset / Trial / NCT01000896

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

NCT01000896

Phase 1 Withdrawn 27 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.

Timeline

Start
2010-01
Primary completion
2010-09
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject saracatinib Small molecule Oral
Background Carboplatin Small molecule Intravenous
Background Paclitaxel Small molecule Intravenous